BeyondSpring (NASDAQ:BYSI) Releases Earnings Results, Beats Estimates By $0.49 EPS

BeyondSpring (NASDAQ:BYSI) released its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.49, Zacks reports.

BeyondSpring Stock Up 0.0%

Shares of BYSI stock traded up $0.00 during trading on Friday, reaching $0.60. 33,174 shares of the company’s stock were exchanged, compared to its average volume of 143,847. BeyondSpring has a twelve month low of $0.42 and a twelve month high of $2.44. The firm’s fifty day moving average price is $0.66 and its 200-day moving average price is $1.22. The stock has a market capitalization of $24.72 million, a PE ratio of -5.01 and a beta of -0.12.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of BeyondSpring from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.

BeyondSpring Company Profile

BeyondSpring is a biopharmaceutical company focused on developing therapies for cancer and complications associated with cancer treatment. Its research and development activities center on oncology drug candidates and supportive-care treatments. The company’s lead candidate is plinabulin, a small-molecule drug being investigated for use in preventing chemotherapy-induced neutropenia, a potentially serious drop in infection-fighting white blood cells. BeyondSpring has also studied plinabulin for its potential anti-cancer effects, including in lung cancer.